Imagin Medical Inc. (IMEXF)
Chart Events
Performance Outlook
| Previous Close | 0.1930 |
| Open | 0.1930 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1930 - 0.1930 |
| 52 Week Range | 0.0700 - 0.4400 |
| Volume | |
| Avg. Volume | 3,304 |
| Market Cap | 2.261M |
| Beta (5Y Monthly) | 1.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma's Nano-in™ and No-Pass Mimic™ Nanoparticle Technologies in Anti-Aging and Other Products Initially for Skin
Ponce Therapeutics, Inc., a company leveraging the growing scientific knowledge surrounding the aging process to develop anti-aging technologies, announced today that it had executed a worldwide, exclusive license to Speratum's proprietary Nano-in™ and No-Pass Mimic™ technologies to advance its lead product, ReBeaut™, a state-of-the-art biotechnology platform to restore the youthful balance of aged or "senescent" and young, vital cells in the skin, targeting the senescent cells for elimination,
- PR Newswire
Imagin Medical Announces Stock Option Grants
Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) ("Imagin" or the "Company") today announced today that, pursuant to the Company's Stock Option Plan, an aggregate of 472,187 shares have been granted to certain employees, board members and consultants as incentive stock options at an exercise price of $0.28 USD per share. The options are exercisable for a period of five years, ending on April 22, 2027.
